• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

B. Braun, Infraredx to collaborate on drug-coated balloon catheter IDE study

March 31, 2021 By Sean Whooley

B. Braun Interventional Systems InfraredxB. Braun Interventional Systems (BIS) announced today that it is collaborating with Infraredx on a trial for the B. Braun SeQuent Please ReX.

Bethlehem, Pa.-based BIS, a B. Braun affiliate, and Infraredx, a Nipro company, will work together to accelerate the FDA investigational device exemption (IDE) clinical trial for the SeQuent Please ReX drug-coated PTCA balloon catheter, which received breakthrough device designation in 2019.

The SeQuent Please ReX drug-coated PTCA balloon catheter is designed to treat coronary in-stent restenosis (ISR), or the gradual re-narrowing of a coronary artery following stent implantation, according to a news release.

Under the collaboration, BIS and Infraredx plan to utilize both companies’ resources to pool clinical expertise and financial resources to accelerate and execute the U.S. study.

“B. Braun and Nipro have worked together over the last decade to arm vascular specialists in Europe and Asia with alternative therapies for coronary interventions,” Infraredx president & CEO Nozomu Fujita said in the release. “Our decision to also align the resources of our U.S. entities will accelerate how quickly U.S. Interventionalists will be able to access the SeQuent Please ReX technology for U.S. clinical trials.”

B. Braun has sold more than 1 million SeQuent Please drug-coated PTCA balloon catheters. The company developed the SeQuent Please ReX — a variation on the current portfolio sold outside the U.S  — exclusively for the U.S. market.

“Over the last decade, together with Nipro, we have been able to develop the market for coronary drug-coated balloons by delivering high-quality clinical evidence and optimal physician and patient access,” B. Braun Melsungen AG Vascular Systems director of medical, scientific & regulatory affairs Dr. Philip Steen said. “Aligning with Infraredx to work toward bringing the SeQuent Please Technology to the U.S. marketplace through the U.S. IDE process is a logical next step to address an important unmet clinical need.”

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: B. Braun Interventional Systems, Infraredx

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS